The key pharmaceutical trends from 2023 according to industry leaders

There has been no shortage of excitement over 2023 with a huge number of impactful stories.

We have seen big funding rounds investments going into pharmaceutical players, such as a $51 million Series B round​ raised by the Parkinson’s disease player Cerevance in February and an impressive $210 million round​ raised in September to power Nimbus Therapeutics’ computational drug discovery.

Additionally, the pharmaceutical supply chain attracted major cash injections with one being a $57 million investment​ into Swiss-based tech firm SkyCell by M&G Investments in October. Meanwhile, venture capital (VC) funders also received big attention, with one notable example being Carlyle’s Abingworth, which capped its Clinical Co-Development Co-Investment Fund (CCD-CIF) at $356 million in November​.

This year also saw major acquisitions, with some of the biggest being Danaher’s takeover​ of Abcam for $5.7 billion in August and the acquisition​ of Iveric Bio by Astellas Pharma for $5.9 billion in May.

No less important were the numerous regulatory approvals, such as the US and EU’s green light​ for Astellas’ fezolinetant for the treatment of hot flashes associated with menopause. And more approvals could be incoming, with promising trial results from compounds such as AstraZeneca’s osimertinib​ (Tagrisso) for the treatment of specific forms of early-stage non-small cell lung cancer (NSCLC).

There are also many key trends and challenges that 2023 presented. We turned to five key opinion leaders in the industry for their takes on the progress of the pharmaceutical industry in 2023, its challenges and their perspectives of 2024.

Leave a Reply

Your email address will not be published. Required fields are marked *